BCL2 and cancer: To reduce the on-target toxicity of the earlier generation of inhibitors, ABT-199 (venetoclax), a BCL-2-specific inhibitor, was developed and can potently induce apoptosis in BCL-2-dependent cancer cells, but not BCL-XL-dependent cancer cells [53].